Intracerebral Hemorrhage (ICH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Intracerebral hemorrhage (ICH), a subtype of stroke, is a severe condition characterized by the formation of a hematoma within the brain parenchyma, sometimes extending into the ventricles. Accounting for 10-15% of all strokes, non-traumatic ICH is linked with significant morbidity and mortality. Risk factors for ICH encompass chronic hypertension, amyloid angiopathy, anticoagulant medication use, and vascular malformations. Seizures often manifest as part of the initial symptoms of ICH, though in some instances, they may present as a delayed complication occurring approximately two hours post-hemorrhage. The diagnostic cornerstone for ICH remains a non-contrast CT scan of the head due to its accessibility and rapidity. Additionally, MR angiography and MR venography can identify vascular abnormalities such as arteriovenous malformations and cavernomas. For patients on vitamin K antagonists, guidelines recommend the management of spontaneous ICH by correcting coagulopathy, aiming for an INR < 1.4. Correction methods may include the administration of fresh frozen plasma (FFP), vitamin K, prothrombin complex concentrates, and recently developed recombinant activated factor VIIa.
Thelansis’s “Intracerebral Hemorrhage (ICH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Intracerebral Hemorrhage (ICH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Intracerebral Hemorrhage (ICH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Intracerebral Hemorrhage (ICH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
_page-0001.jpg)
Comments
Post a Comment